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Abstract 
Objectives: Interleukin-18 binding protein (IL-18BP) is functioning as a natural anti-inflammatory 
and immunosuppressive molecule by neutralizing the effects of IL-18 during inflammation. This 
study aimed to identify the role of IL-18BPa in the regulation of immune responses associated with 
the pathogenesis of RA. 
Materials and Methods: 65 RA patients, 22 OA patients, and 40 sex and age matched healthy 
donors were enrolled in this study. Synovial specimens were obtained through synovectomy or 
arthroscopic procedures. SFMC and PBMC were prepared by using Ficoll-Hypaque separation 
procedure. Superarray analysis was used to measure the expression profile of immune-related genes 
in normal PBMC treated with recombinant human IL-18BPa.The mRNA levels of Th1 and Th2 
cytokines were measured by Real-time PCR, and the protein levels of IFN-γ, IL-4 were detected by 
ELISA.  
Results: SuperArray analysis of immune related gene expression profile in normal PBMC treated 
with IL-18BPa indicated decreases in the gene expression of IFN-γ and its regulatory molecules 
STAT-1 and STAT-2. This study pointed out that IL-18BPa has additional anti-inflammatory 
property through downregulating the expression of IFN-γ and IL-12, at the same time, upregulating 
the expression of IL-4 and IL-10.  Both IFN-γ and IL-12 could upregulated the mRNA and protein 
levels of IL-18BPa in both the normal and RA subjects.  
Conclusion: Our results demonstrated the importance of IL-18BPa as an immune regulatory 
molecule and as a promising therapy for treating RA. 
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heumatoid Arthritis (RA) is a chronic 
inflammatory disease that affects 
approximately 1% of the population in 
all parts of the world1.   
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Although the etiology and pathogenesis of RA 
is unknown, there is evidence indicating that 
T-cell mediated inflammation plays an 
important role in the rheumatoid synovitis. 
Several data suggest that T lymphocytes, in 
particular, Th1 cells, and array of 
proinflammatory cytokines and monokines 
are associated with inflammation and tissue 
damage in RA2, 3. Certain cytokines such as 
IL-18 has been found to exhibits powerful 
Th1 promoting activities in synergy with IL-
12 in RA4. Still the molecular mechanisms 
involved in the activation and perpetuation of 
inflammatory T cells in rheumatoid synovium 
are poorly understood. 
Novick et al.5 identified IL-18BP as the 
natural inhibitor of IL-18. This gene product 
is an important potential candidate for 
neutralizing IL-18 in autoimmune diseases5, 6. 
As such; it regulates IL-18-induced IFN-g  
R
K.E. Khalid et al.                                           Interleukin 18 Binding Protein in Rheumatoid Arthritis 
 





production and consequently influences the 
Th1 and inflammatory responses. IL-18BP 
resembles the extracellular segment of a 
cytokine receptor in a single Ig domain. 
However, IL-18BP is a novel protein distinct 
from IL-1 and IL-18 receptor family 
members.  
MATERIALS AND METHODS 
A total of 65 Chinese patients with 
Rheumatoid Arthritis (RA), 22 patients with 
Osteoarthritis (OA), and 40 sex and age 
matched healthy donors were included in this 
study under the informed consent and the 
approval by the Institutional Medical Ethics 
Review Board of the Shanghai Institutes of 
Biological Sciences, Chinese Academy of 
Sciences. Diagnosis of RA was defined 
according to the classification criteria of 
American College of Rheumatology7. All 
patients were from different parts of China, 
they referred to the Department of 
Rheumatology out clinic of Renji Hospital in 
Shanghai (China) in the period between 2005- 
2007.  
Patients received any immunosuppressive or 
immunomodulatory drugs in the last two 
month preceding samples collection were 
excluded. RA patients group included 58 
female and seven male with average age of 
53±9.8 years. Synovial specimens were 
obtained through synovectomy or 
arthroscopic procedures that were performed 
for other medical indications. Synovial fluids 
(SF) were centrifuged at 350g for three 
minutes, and supernatants were collected and 
immediately stored at –80ºC until use. 
Mononuclear cells were prepared by Ficoll-
Hypaque separation (Amersham Biosciences) 
from SF, and blood specimens of RA patients 
and were immediately processed for cell 
culture. 
Cell culture: 
PBMC from healthy Chinese donors and RA 
patients were cultured in flat bottomed wells 
at 1X10 6 cells/ml in RPMI stimulated with 
different concentration of IL-18BPa (5 ng/ml, 
50 ng/ml, 200 ng/ml). After 48 hrs, IFN-g, 
IL-12, IL-4, IL-10 were measured by real 
time PCR (Q-PCR).  
 
To study the adverse effect of blocking IL-
18BP in RASF, normal PBMC was co-
cultured with RA-SF pre-incubated with anti-
human IL-18BPa antibody in a dose-
dependant manner for 48 hrs, IFN-g mRNA 
was quantitated by Real-time PCR (Q-PCR). 
To see the Effect of Th1 and Th2 cytokines 
on IL-18BPa production, PBMC (1X106 
cells/ml in RPMI 1640 medium with 10% 
fetal calf serum ) from healthy donors (n=10) 
were cultured for 7 days in duplicate with or 
without IFN-g (5ng/ml), IL-12 (1ng/ml), IL-
4 (5ng/ml), and IL-10 (10ng/ml) or Anti-CD3 
Antibody (1mg/ml).  
 
cDNA array analysis: The expression 
analysis of selected cytokine and chemokine 
genes were examined using a commercially 
available cDNA array system containing 364 
genes related to autoimmune and 
inflammatory response and 20 positive and 
negative control genes (SuperArray 
Bioscience Corporation, MD) according to 
the manufacturer’s instructions. The gene list 
is given at the supplier’s website 
(ww.superarray.com). Briefly, PBMC from 
healthy individuals were treated with IL-
18BPa (0.2 mg/ml) for 48hrs. The gene 
expression profile was compared with 
untreated PBMCs under the same 
experimental condition. Three micrograms of 
total RNA were reversed transcribed into 
bioti-16-deoxy-UTP-labeled single strand 
cDNA by Moloney murine leukemia virus 
reverse transcriptase. After pre-hybridization, 
membranes were hybridized with biotin-
labeled sample cDNA and incubated with 
alkaline-phosphatase-conjugated streptavidin. 
Chemiluminescence was visualized by 
autoradiography. The results were analyzed 
using GEArray Expression Analysis Suite 
(Version1.0) provided by SuperArray at its 
website. The relative expression of different 
genes was estimated by comparing signal 
intensity with that of average intensity of 
internal control genes. Data was expressed as 
ratio of significant change in gene expression 
(IL-18bp treated/untreated control). 
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The concentrations of the indicated IFN-g 
and IL-4 cytokines were measured 
quantitatively using ELISA kits (Jingmei 
Biotech.) according to the manufacturer’s 
procedure. SF, plasma or serum, along with 
the recombinant cytokines as standards, were 
diluted with PBS and added in duplicate 
wells. Plates were incubated for 2 hours and 
subsequently washed with PBS-Tween 20. 
Matched biotinylated detecting antibodies 
were added and incubated for 2 hours. After 
washing, avidin-conjugated HRP and 3,3′,5,5-
tetramethyl benzidine were used for color 
development. Optical density was measured 
and cytokine concentrations were quantitated 
using microplate computer software (Bio-Rad 
Laboratories). 
RNA extraction and Real time PCR:  
Total RNA was isolated from cell pellets 
using an RNeasy Minikit (QIAGEN) with 
additional DNA digestion step (RNase-Free 
DNase Set; QIAGEN). First-strand cDNA 
synthesis was performed for each RNA 
sample using Sensiscript RT Kit (QIAGEN). 
Random hexamers were used to prime cDNA 
synthesis. SYBR green real-time PCR primers 
for human IL-18BP isoforms, selected 
cytokines, and GAPDH (housekeeping 
control) were designed using Primer Express 
software from Invitrogen (Table 1). The 
specificity and optimal primer concentration 
was tested. Thermocycler conditions included  
 
 
an initial holding at 50°C for 2 minutes, then 
95°C for 10 minutes; this was followed by a 
2-step PCR program: 95°C for 15 seconds and 
60°C for 60 seconds for 40 cycles. Data were 
collected and quantitatively analyzed on an 
ABI PRISM 7900 sequence detection system 
(Applied Biosystems). The GAPDH gene was 
used as an endogenous control to normalize 
for differences in the amount of total RNA in 
each sample. All values were expressed as 
fold increase or decrease relative to the 
expression of GAPDH. The mean value of the 
replicates for each sample was calculated and 
expressed as cycle threshold (CT, cycle 
number at which each PCR reaction reaches a 
predetermined fluorescence threshold, set 
within the linear range of all reactions). The 
amount of gene expression was then 
calculated as the difference (ΔCT) between 
the CT value of the sample for the target gene 
and the mean CT value of that sample for the 
endogenous control (GAPDH). Relative 
expression was calculated as the difference 
(ΔΔCT) between the ΔCT values of the test 
sample and of the control sample. Relative 
expression of genes of interest was calculated 
and expressed as 2–ΔΔCT. 
Statistics: A student’s t test was used to 
analyze the difference between the groups. 
Gene expression differences were analyzed by 
the Mann-Whitney U test. A value of p<0.05 
was considered statistically significant.
                       Table 1: Specific primers designed for real-time PCR (Q-PCR) analysis 
Name Primer Sequence (5´------3´) Product length 
(bp) 
IFN-g FW TCAGCTCTGCATCGTTTTGG 120 
 RV GTTCCATTATCCGCTACATCTGAA  
IL-12 FW TGGAGTGCCAGGAGGACAGT 147 
 RV TCTTGGGTGGGTCAGGTTTG  
IL-10 FW GTGATGCCCCAAGCTGAGA 138 
 RV CACGGCCTTGCTCTTGTTTT  
IL-4 FW CCACGGACACAAGTGCGATA 149 
 RV CCCTGCAGAAGGTTTCCTTCT  
 
 
FW = Forward; RV = Reverse.Bp = Base pair 
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A total of 65 Chinese patients with RA, 22 
patients with OA, and 40 sex and age matched 
healthy donors were included in this study. 
RA patients group included 58 females. The 
average age ± standard deviation (SD) was  
 
 
53±9.8 years. Table 2 summarized the 
demographic and clinical data of the RA and 
OA patients referred to the outpatient clinic of 
Renji Hospital in Shanghai in the period 
between September 2005-2007. 
 
 
Table 2: Demographic and clinical data of the RA and OA patients referred to the  
       out clinic of Renji Hospital in Shanghai in the period between September 2005-2007. 
 
 
Parameters RA (n=65) OA (n=22) 
Age (mean ± SD) in years           53±9.8 70±8.3 
Disease duration (mean ± SD) in years         10.6±6.6 11±7.8 
Sex of (male/female)              7/58              4/18 
ESR mean± SD  mm/hour         44.9±28.9  26±13.6 
Positive Rheumatoid factor (%)              85.1    NA 
IgG Rheumatoid Factor ± SD       532.1±923.9    NA 
IgA Rheumatoid Factor ± SD       454.0±608.1    NA 






Inhibition of IL-18BPa to the gene 
expression and production of Th1 cytokine: 
First, we examined the expression profile of 
genes related to autoimmune and 
inflammatory response in normal subjects. A 
representative ex-vivo experiment 
representing the expression profile of selected 
genes of 20 positive and negative control 
genes in normal PBMC treated with IL-
18BPa (GEArray S Series human 
autoimmune and inflammatory response gene 
array, SuperArray Bioscience corporation, 
MD). Notably, IFN-g gene expression was 
decreased in treated PBMC compared to non 
treated one. In parallel to gamma interferon, 
STAT-1 and STAT-4 gene expression was 
also decreased as shown in Table 3.  
From the aforementioned results, we 
hypothesized that IL-18BPa may have further 
anti-inflammatory property through 
decreasing the expression of Th1 cytokines 





To this end, the in-vitro results in normal and 
RA-PBMC indicated the ability of IL-18BPa 
to inhibit the mRNA levels of IFN-g and IL-
12 (Figure 1 A1&A2)  and as well as, it can 
augment the mRNA levels of Th2 cytokines 
represented in IL-10 and IL-4 (Figure 1 
A3&A4). The above result was confirmed by 
doing ELISA for IFN-g and IL-4 (Figure 1 
B1&B2).  
Next we addressed whether blocking IL-
18BPa in RASF could reverse the results 
indicated in figure 2A. SF of RA patients 
were pre-incubated for 45 min with different 
concentration of human Anti-IL-18BPa 
antibody (R&D System). PBMC preparations 
were then exposed in-vitro to the indicated 
dilution (Figure 1 B3) of the treated SF for 
48hours. PBMC cells were subsequently 
harvested and quantitatively analyzed for the 
mRNA expression of IFN-g and IL-12. 
Altogether, these results highlighted the anti-
inflammatory properties that IL-18BPa can 
play in RA synovium. 
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Table 3: Gene expression profile normal PBMC after treated with IL-18BPa Gene groups                   
Genes altered Ratio 
 
 
Description of increased genes  
Colony stimulating factor 2 (granulocyte-macrophage)      79.51 
Toll-like receptor 9 5.02 
Chemokine (C-X-C motif) ligand 6 4.82 
Vascular endothelial growth factor 3.73 
Mitogen-activated protein kinase 8 3.26 
Forkhead Box P3 2.34 
Interleukin 12B 2.14 
Description of decreased genes  
Interferon, gamma 0.07 
Suppressor of cytokine signaling 4 0.02 
Signal transducer and activator of transcription 4 (STAT-4) 0.01 
Chemokine (C-C motif) ligand 17 0.01 
CAMP responsive element binding protein 1 0.01 
Interleukin 9 0.01 
Signal transducer and activator of transcription 1 (STAT-1) 0.01 
Interleukin 19 0.00 
Inducible T-cell co-stimulator 0.00 
Sp3 transcription factor 0.00 
 
Effect of Th1 and Th2 cytokines on IL-18BPa 
production:   
Our result indicates that IL-18BPa can be 
induced by a variety of proinflammatory 
cytokines. PBMC from normal subjects was 
treated for 7 days with optimum concentration 
of IFN-g (5mg/ml), IL-12 (1mg/ml), TNF-a 
(5 mg/ml), IL-4 (5mg/ml), and IL-10 (10 
mg/ml) with or without anti-CD3 antibody 
stimulation (1mg/ml). As shown in figure 2 
A1&A2, IL-18BPa expression was 
significantly up regulated by IFN-g and IL-
12 in a dose-dependant manner.                        
 
 
In conformity, IFN-g, IL-12 could augment 
the production of IL-18BPa protein in-vitro in 
RA subjects (Figure 2 B1&B2). 
Discussion: 
An increase in IL-18 and its neutralizing 
inhibitor (IL-18BP) has been reported in RA 
serum compared with control8. 
The cDNA array gene analysis in normal 
PBMC treated with recombinant IL-18BPa 
observed down regulation to IFN-g gene 
production comparable with the signal 
transducer and activator of transcription 1 
(STAT-1) and 4 (STAT-4), which are 
involved in IFN-g production9,10.  
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Regulatory effect of IL-18BPa on Th1 and Th2 mRNA transcripts and protein levels. The results 
are expressed as mean value of relative mRNA expression of transcript ± SEM. Single asterisk 
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Figure 2: IL-18BPa production and mRNA expression by control peripheral blood mononuclear 
cells (PBMC). Bars showed the significant levels as mean ± SD of independent experiments 
performed with supernatant and cells from different healthy donors. Asterisks indicate significant 
different (*P< 0.05). 
 
This notion led us to go deep and see whether 
IL-18BPa may have an effect on the cytokines 
milieu in RA and normal subjects, taken into 
account a previous studies highlighted in a 
way or another, an indirect inhibition of IFN-
g by IL-18BPa5. This in addition to the 
function of IL-18BPa as an early inhibitor to 
Th1 cytokines in animal models following IL-
18BPa administration in CIA models, and 
abrogate circulating IFN-g following LPS 
injection5,11. Furthermore, the level of IFN-g 
was found significantly reduced in serum of 
mice transgenic to IL-18BP compared to non 
transgenic ones12. Also it has been found that 
the administration of IL-18BPa resulted in 
diminution of the local production of IFN-g 
in patients with allergic contact dermatitis13. It 
could also reduces iNOS, TNFa and IFN-g 
in Rats model administered with IL-18BP 
antibody used as control group in kidney 
allograft rejection14. In other compelling 
study, IL-18BPa was found down regulating 
IL-12 induced IFN-g production in RA- and 
normal PBMCs15.  
Compared to aforementioned results, here we 
observed an anti-inflammatory effect for IL-
18BPa by reducing the release and expression 
of Th1 type cytokines represented in IFN-g 
and IL-12. As well IL-18BPa has the ability 
to up regulated the expression and production 
of Th2 type cytokines represented in IL-4 and 
IL-10. Furthermore, blocking IL-18BPa in 
RA-SF increased the expression of IFN-g in 
a dose-dependant manner.  
Herein, the study found that both IFN-g and 
IL-12 have the ability to enhance IL-18BPa 
production in a significant level, however, the 
other Th1 cytokines including IL-23, IL-1b, 
and TNF-a can augment IL-18BPa 
production.  
We also found that, the expression of IL-
18BPa was significantly increased by IFN-g 
and IL-12 in a dose-dependant manner. 
Likewise, IL-18BPa was strongly expressed  
by IL-12 mediated through IFN-g in PBMC 
of healthy subjects 16. However, only gamma 
interferon (IFN-g) has the ability to up 
regulate the mRNA level of IL-18BPa in 
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synoviocytes17, endothelial cells and 
macrophages3, and in non leukocytes cells18.  
The discrepancy between our results and that 
reported by Kawashima and Miossec15, who 
found that IL-12 decreases the basal levels of 
IL-18BPa production by freshly isolated RA 
or control PBMCs, may be due to differences 
in assay condition, as well as, the different 
stimulation and application procedures used. 
In summary, in-vitro analysis indicated 
further anti-inflammatory properties to IL-
18BPa on cytokines milieu, and IL-18BPa 
interaction with IFN-g and IL-12 could 
represent a negative feedback mechanism 
upon established RA inflammation. Defining 
the roles of IL-18BPa and gaining a better 
understanding of the molecular function will 
facilitate the administration of IL-18BPa as 
promising therapy for treating RA and 
possibly other autoimmune diseases. 
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